EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Novel Small Molecules in IBD: Current State and Future Perspectives

André Jefremow, Markus F Neurath

Cells · 2023

DOI: 10.3390/cells12131730 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2023. Verfasst von André Jefremow und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine 1, University Erlangen-Nürnberg, 91054 Erlangen, Germany. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases, Biological Products. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation (DFG).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biologicals have dominated the therapeutic scenery in inflammatory bowel diseases (IBDs), namely ulcerative colitis (UC) and Crohn’s disease (CD), for the past 20 years. The development of tofacitinib was the starting point for an era of small molecules after the era of biologicals. These new agents may challenge the use of biological agents in the future. They share properties that appeal to both patients and physicians. Low production costs, a lack of immunogenicity, and ease of use are only some of their benefits. On the other hand, patients and their physicians must manage the potential side effects of small molecules such as JAK inhibitors or S1P1R modulators. Here, we present agents that have already entered the clinical routine and those that are still being investigated in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesBiological ProductsHumans

Stichwörter der Autor:innen

Crohn’sJAKinflammatory bowel diseasessmall molecular drugssmall moleculesulcerative colitis

Substanzen

Biological Products

Autor:innen und Institutionen

  • Department of Medicine 1, University Erlangen-Nürnberg, 91054 Erlangen, Germany.
  • Deutsches Zentrum Immuntherapie (DZI), 91054 Erlangen, Germany.
  • Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.

Förderung

  • German Research Foundation (DFG)

Zitieren

APA

Jefremow, A., & Neurath, M. F. (2023). Novel Small Molecules in IBD: Current State and Future Perspectives. Cells. https://doi.org/10.3390/cells12131730

Vancouver

Jefremow A, Neurath MF. Novel Small Molecules in IBD: Current State and Future Perspectives. Cells. 2023. doi:10.3390/cells12131730

BibTeX
@article{Jefremow2023,
  author = {Jefremow, André and Neurath, Markus F},
  title = {Novel Small Molecules in IBD: Current State and Future Perspectives},
  journal = {Cells},
  year = {2023},
  doi = {10.3390/cells12131730}
}
Kostenlos starten →